15.12
1.18%
-0.18
Handel nachbörslich:
15.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Clinical Oncology Next Generation Sequencing (NGS) Market - openPR
Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN
Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Breast Cancer Screening and Diagnostic Techniques Market - openPR
Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst Downgrade - MarketBeat
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire
Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance
SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer - GlobeNewswire Inc.
Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire
Long Term Trading Analysis for (MYGN) - Stock Traders Daily
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times
Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia
Myriad Genetics Inc (MYGN) Shares Gap Down to $16.76 on Nov 12 - GuruFocus.com
Myriad Genetics: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
How Myriad Genetics helped address the gap in genetic testing among women - Ad Age
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - AccessWire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
U.S. Women Health Laboratory Testing Market to Witness - openPR
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics Inc (MYGN) Quarterly 10-Q Report - Quartzy
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... - Yahoo Finance
Myriad Genetics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Myriad: Q3 Earnings Snapshot - Marketscreener.com
Myriad Genetics Inc Reports Q3 2024 Revenue of $213 Million, Bea - GuruFocus.com
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation - AccessWire
Pancreatic Cancer Market Expected to Reach $5.7 Billion by 2031 | - openPR
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - PR Newswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announ - WICZ
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out - AccessWire
Cancer Diagnostics Market 2024-2031 Product Size Analysis: - openPR
Myriad Genetics holds stock target after UNH update By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%What's Next? - MarketBeat
Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):